Concept	Search terms	No. of	
		studies	
Gastrointestinal	'gastrointestinal':ab,ti	326,277	
Bleeding	'hemorrhage':ab,ti OR	480,791	
	'haemorrhage':ab,ti OR		
	'bleeding':ab,ti		
Gastrointestinal	#1 AND #2	46,910	
bleeding			
Epidemiology	'incidence':ab,ti OR 'prevalence':ab,ti	2,786,642	
	OR 'epidemiology':ab,ti OR		
	'mortality':ab,ti OR 'case fatality':ab,ti		
Epidemiology of	#3 AND #4	12,875	
gastrointestinal			
bleeding			
Limits	#5 AND ([article]/lim OR	4,793	
	[review]/lim) AND [humans/lim		
	AND [English]/lim AND		
	([embase]/lim OR [medline/lim)		
	Concept Gastrointestinal Bleeding Gastrointestinal bleeding Epidemiology fepidemiology astrointestinal bleeding Limits	ConceptSearch termsGastrointestinal'gastrointestinal':ab,tiBleeding'hemorrhage':ab,tiOR'haemorrhage':ab,tiOR'bleeding':ab,tiORGastrointestinal#1 AND #2bleeding'incidence':ab,ti OR 'prevalence':ab,tiEpidemiology'incidence':ab,ti OR 'prevalence':ab,tiOR'epidemiology':ab,tiOR'mortality':ab,ti OR 'case fatality':ab,tiOREpidemiologyof#3 AND #4gastrointestinal#5AND ([article]/limbleedingImits#5Limits#5AND [humans/limAND[English]/limAND([embase]/lim OR [medline/lim)	

Supplementary Table 1. Full electronic search strategy.

Notes:

Terms restricted to abstract and title (ab:ti).

Results were excluded if conference abstract/paper/review, editorial, letter, note or short survey.

The search was conducted on September 17, 2019.

Supplementary Table 2. Assessment of risk of bias by Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies with amendments.

Domain	Item	Question	Risk	Explanation		
			category			
D1	Target population	Was the sample frame appropriate to address the target population?	Low Unclear	Patient population is identified that would be susceptible gastrointestinal bleeding. The region for which the estimat data will be applied to also needs to be specified. Patient population is not clear; e.g. either the age range		
		population.	High	setting is not addressed clearly. Target population is not identified.		
	Sampling	Were study participants	Low	All people are recruited in the sample frame which is appropriate. If there is sampling, this should be done at random and justified. In hospital surveys, the hospitals also need to be sampled randomly.		
D2	participants	rticipants recruited in an appropriate way?	Unclear	It is not clear whether the recruited patients are sampled from a larger population pool.		
			High	Recruitment strategy indicates non-random sampling, susceptible to bias, or method of recruitment is not		

				mentioned at all.
				The study justifies the target population to be fully captured
			Low	from a large enough database to provide population
				estimates, otherwise sample size calculation is conducted.
D2	Comple size	Was the comple size a deguate?	Uncloar	It is unclear whether the data source is adequately large to
D5	Sample size	was the sample size adequate?	Unclear	obtain population estimates.
				Information is not provided on sample size calculation when
			High	data source is not large enough or less participants are
				recruited than the calculated sample.
				Population demographics and setting are provided in
		Were the study subjects and d setting described in detail?	LOW	sufficient detail.
	Describing		Unclear	Some information on population demographics and setting
D4				are missing (e.g. age or gender characteristics not provided
D4	sotting			sufficiently, relevant information on the setting is not given)
	setting			Population characteristics or setting are not mentioned at all
			High	or clearly demonstrate to be not corresponding to the target
				population.
		Was data analysis conducted	Since the sti	idu does not include natient-renorted data, coverage bias will not be
Removed item		with sufficient coverage of the		ing noes not include pullent-reported data, coverage blus will not be
		identified sample?		

			Low	Established diagnostic criteria or guidelines are used (e.g.
	Classification	Were valid methods used for the		ICD)
D5	bias	identification of the condition?	Unclear	Accurate definition of the disease being provided with no
	0100		Officieur	established criteria.
			High	No disease definition or incorrect definition is present.
			Low	Data are collected by trained personnel or medical staff.
	Maaguramant	Was the condition measured in a	Uncloar	Information on the level of expertise on the data collectors is
D6 method	method	standard, reliable way for all participants?	Unclear	not clear.
	metriou		High	Data collection source is not mentioned or the method of
				measurement is not appropriate.
				Data of interest is reported; for studies which provide
	Statistical		Low	population estimates the number of events and population
				size are both adequately provided with confidence intervals.
D7			Uralaar	Some data of interest is reported but there is missing
	anarysis	analysis?	Unclear	information on population size and/or confidence intervals.
			Uiah	Results of the study do not include information on necessary
			Ingn	data and/or statistical analysis.
D0	Missing data	Was the response rate adequate,	Louis	Missing data and how they are handled are mentioned.
Do	wissing data	and if not, was the low response	LUW	

	Ingn	provided.		
	High	No information on the comprehensiveness of the response is		
	Unclear	being considered, with no explicit mention of missing data.		
rate managed appropriately?	Unclear	Investigation of quality or comprehensiveness or data is		

Note: The checklist was amended where necessary for the use of this review. Explanations are presented for the adjusted criteria, considering the design and content of the studies included in this review.

	Item #	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly
		used term in the title or the abstract*
		(b) Provide in the abstract an informative and
		balanced summary of what was done and what
		was found*
Introduction		
Background/rationale	2	Explain the scientific background and rationale for
		the investigation being reported*
Objectives	3	State specific objectives, including any
		prespecified hypotheses*
Methods		
Study design	4	Present key elements of study design early in the
		paper*
Setting	5	Describe the setting, locations, and relevant dates,
		including periods of recruitment, exposure,
		follow-up, and data collection*
Participants	6	(<i>a</i>) Cohort study – Give the eligibility criteria, and
		the sources and methods of selection of
		participants. Describe methods of follow-up*
		Cross-sectional study – Give the eligibility criteria,
		and the sources and methods of selection of
		participants*
		(b) Cohort study—For matched studies, give
		matching criteria and number of exposed and
		unexposed
		Case-control study-For matched studies, give
		matching criteria and the number of controls per
		case

Supplementary Table 3. Adaptation of *Strengthening The Reporting of Observational Studies in Epidemiology (STROBE)* guidelines for study assessment.

Variables		7	Clearly define all outcomes, exposures, predictors			
			potential confounders, and effect modifiers. Give			
			diagnostic criteria, if applicable			
Data	sources/	8	For each variable of interest, give sources of data			
measuremer	nt*		and details of methods of assessment			
			(measurement). Describe comparability of			
			assessment methods if there is more than one			
			group			
Bias*		9	Describe any efforts to address potential sources			
			of bias*			
Study size*		10	Explain how the study size was arrived at			
Quantitative	2	11	Explain how quantitative variables were handled			
variables*			in the analyses. If applicable, describe which			
			groupings were chosen and why			
Statistical m	ethods*	12	(<i>a</i>) Describe all statistical methods, including those			
			used to control for confounding*			
			(b) Describe any methods used to examine			
			subgroups and interactions*			
			(c) Explain how missing data were addressed*			
			(<i>d</i>) Cohort study—If applicable, explain how loss			
			to follow-up was addressed			
			Cross-sectional study-If applicable, describe			
			analytical methods taking account of sampling			
			strategy			
			(<u>e</u>) Describe any sensitivity analyses*			
Results						
Participants		13	(a) Report numbers of individuals at each stage of			
			study-e.g. numbers potentially eligible, examined			
			for eligibility, confirmed eligible, included in the			
			study, completing follow-up, and analyzed			
			(b) Give reasons for non-participation at each stage			

		(c) Consider use of a flow diagram
Descriptive data	14	(a) Give characteristics of study participants (e.g.
		demographic, clinical, social) and information on
		exposures and potential confounders*
		(b) Indicate number of participants with missing
		data for each variable of interest*
		(c) Cohort study-Summarize follow-up time (e.g.,
		average and total amount)*
Outcome data	15	Cohort study-Report numbers of outcome events
		or summary measures over time*
		Cross-sectional study – Report numbers of outcome
		events or summary measures*
Main results	16	(a) Give unadjusted estimates and, if applicable,
		confounder-adjusted estimates and their precision
		(e.g., 95% confidence interval). Make clear which
		confounders were adjusted for and why they were
		included
		(b) Report category boundaries when continuous
		variables were categorized
		(c) If relevant, consider translating estimates of
		relative risk into absolute risk for a meaningful
		time period
Other analyses	17	Report other analyses done-e.g. analyses of
		subgroups and interactions, and sensitivity
		analyses*
Discussion		
Key results	18	Summarize key results with reference to study
		objectives*
Limitations	19	Discuss limitations of the study, taking into account
		sources of potential bias or imprecision. Discuss
		both direction and magnitude of any potential bias*

Interpretation	20	Give a cautious overall interpretation of results
		considering objectives, limitations, multiplicity of
		analyses, results from similar studies, and other
		relevant evidence*
Generalizability	21	Discuss the generalizability (external validity) of
		the study results*
Other information		
Funding	22	Give the source of funding and the role of the
		funders for the present study and, if applicable, for
		the original study on which the present article is
		based*

Note: STROBE checklist was altered such that criteria regarding interventional studies were disregarded. Five items were removed and marked with asterisks (*), since they were already covered by the risk of bias assessment.

Hierarchical	General reason for	Definition	No. of	
order for exclusion	exclusion category (as presented in PRISMA flowchart)		studies	
1	Article not in English	Full-text article not in English, even if the abstract is translated	2	
2	Review articles	Systematic and narrative reviews corresponding to the objectives of the current study; of which bibliographies will be reviewed	27	
3	Overlapping study population	Different publications with the same or overlapping population of patients	9	
4	Wrong diagnosis	Studies only including those with specific sites of GIB (e.g. peptic ulcer bleeding, Mallory-Weiss tears, Dieulafoy's lesion), undefined GIB or overall GIB	49	
5	Wrong study design	Studies that are not population- based (e.g. single hospital studies, modelling studies, sub-sampling)	103	
6	Wrong study population	Stringent exclusion criteria (e.g. drug use, in-patients), not covering all-cause bleeding	32	
7	Wrong study	Not including all presenting with	24	

	population	GIB, e.g. cases matched with controls, pediatric/geriatric population only	
8	Wrong study setting	Patients admitted to certain wards of the hospital or those treated in specialty hospitals only	8
9	Outcome related to intervention	Studies that involve specific diagnostic or treatment procedure, which is not otherwise in standard of care	14
10	Wrong study outcome	No epidemiological data of interest, i.e. incidence, mortality or case fatality for the general population not recorded	46
11	Wrong study outcome	Only patient-reported data	3

Supplementary Table 4. Hierarchical order of exclusion criteria presented in PRISMA flowchart.

First author, publication year	D1	D2	D3	D4	D5	D6	D7	D8
Schlup, 1984	+	+	X	-	-	X	-	X
Katschinski, 1989	+	+	X	X	-	-	-	X
Longstreth, 1995	+	+	-	+	+	-	+	-
Bramley, 1996	+	+	X	X	X	-	+	X
Masson, 1996	+	+	X	-	X	-	+	X
Blatchford, 1997	+	+	-	+	X	X	+	+
El Bagir, 1997	-	+	X	+	-	+	+	X
Longstreth, 1997	+	+	-	+	+	-	+	-
Soplepmann, 1997	+	-	X	+	-	-	-	+
Vreeburg, 1997	-	+	-	+	-	+	+	+
Czernichow, 2000	+	+	+	+	-	+	+	+
Paspatis, 2000	+	+	+	+	-	+	+	X
Tenias Burillo, 2001	-	+	-	X	X	-	+	X

Supplementary Table 5. Traffic light plot for risk of bias assessment of each study.

Lewis, 2002	-	+	-	X	+	-	-	X
van Leerdam, 2003	-	+	-	-	-	+	+	+
Targownik, 2006	+	+	+	-	-	-	+	X
Theocharis, 2008	+	+	X	+	-	-	+	+
Kapsoritakis, 2009	+	+	+	+	-	-	+	X
Lanas, 2009	+	+	+	X	+	+	-	+
Loperfido, 2009	+	+	X	+	-	+	+	X
Åhsberg, 2010	-	+	X	+	+	+	+	-
Button, 2011	+	+	+	+	+	+	+	-
Langner, 2011		+	+	X	+	-	-	-
Crooks, 2012	+	+	+	×	+	+	-	+
Laine, 2012	-	+	+	X	+	+	-	-
Miyamoto, 2012	-	-	+	-	-	-	-	X
Mungan, 2012	+	-	+	+	+	+	-	X
Nahon, 2012	+	+	-	+	-	+	+	+

Sangchan, 2012	+	+	-	+	+	-	-	X
Del Piano, 2013	+	-	-	+	-	+	-	-
Hreinsson, 2013a	+	-	-	+	+	+	+	-
Hreinsson, 2013b	-	-	-	+	+	+	+	-
Cavallaro, 2014	+	+	+	+	+	-	-	X
Marmo, 2014	+	-	-	+	-	+	+	-
O'Byrne, 2014	+	+	+	+	+	+	+	-
Abougergi, 2015	+	+	+	+	+	+	+	+
Niikura, 2015	+	X	-	+	-	-	+	-
Taha, 2015	+	+	-	-	-	+	-	-
Lu, 2018	+	+	-	-	-	-	+	-
Park, 2018	+	+	-	+	-	-	+	+
Wuerth, 2018	+	+	+	+	+	+	+	+

		Number of studies (%)				
Item #		Fully	Partially	Not		
		reported	reported	reported		
1	Title and abstract	24 (58.6)	14 (34.1)	3 (7.3)		
Introduc	tion					
2	Background/ratio	38 (92.7)	2 (4.9)	1 (2.4)		
	nale					
3	Objectives	37 (90.2)	4 (9.8)	-		
Methods						
4	Study design	31(75.6)	5 (12.2)	5 (12.2)		
5	Setting	30 (73.2)	7 (17.1)	4 (9.8)		
6	Participants	26 (63.4)	9 (22.0)	6 (14.6)		
7	Variables	30 (73.2)	7 (17.1)	4 (9.8)		
Results						
13	Participants	16 (39.0)	20 (48.8)	5 (12.2)		
14	Descriptive data	17 (41.5)	18 (43.9)	6 (14.6)		
15	Outcome data	36 (87.8)	2 (4.9)	3 (7.3)		
16	Main results	27 (65.9)	9 (22.0)	5 (12.2)		
17	Other analyses	33 (80.5)	1 (2.4)	7 (17.1)		
Discussion						
18	Key results	41 (100.0)	-	-		

Supplementary Table 6. Summary of findings from STROBE assessment upon reporting guidelines.

19	Limitations	29 (70.7)	1 (2.4)	11 (26.8)			
20	Interpretation	41 (100.0)	-	-			
21	Generalizability	11 (26.8)	14 (34.1)	16 (39.0)			
Other information							
22	Funding	30 (73.2)	-	11 (26.8)			

Note: Items 8-12 removed due to repetition of items in risk of bias assessment.

Supplementary Figure 1. PRISMA flowchart of literature search.



Supplementary Figure 2. Summary of risk of bias scoring on each item across studies.

